TSHA

$4.366.60%0.27

Nachbörslich: 4.360.00 0.00%

Taysha Gene Therapies Inc (TSHA)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$4.09

Offen:

$4.08

24-Stunden-Volumen:

3,682,282

Relatives Volumen:

1.49

Marktkapitalisierung:

$1.42B

Einnahmen:

$7.47M

Nettoeinkommen (Verlust:

-$129.88M

KGV:

EPS:

-$0.3962

Netto-Cashflow:

-$115.33M

1W Leistung:

+3.07%

1M Leistung:

-5.83%

6M Leistung:

-34.34%

1Y Leistung:

+2.11%

1-Tages-Spanne:

$4.01$4.38

1-Wochen-Bereich:

$3.92$4.47

52-Wochen-Spanne:

$3.46$7.30

Taysha Gene Therapies Inc Aktie (TSHA) Unternehmensprofil

Firmenname

Taysha Gene Therapies Inc

Sektor

Healthcare

Branche

Biotechnology

Telefon

(214) 612-0000

Adresse

3000 PEGASUS PARK DRIVE, DALLAS, USA

Mitarbeiter

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

TSHA-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Taysha Gene Therapies Inc Aktie (TSHA) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-09-17	Eingeleitet	Wolfe Research	Outperform
2025-10-21	Eingeleitet	Raymond James	Strong Buy
2025-07-11	Eingeleitet	BofA Securities	Buy
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-04-09	Eingeleitet	Piper Sandler	Overweight
2023-02-01	Herabstufung	Jefferies	Buy → Hold
2023-01-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-11-09	Herabstufung	Goldman	Buy → Neutral
2022-03-09	Eingeleitet	Robert W. Baird	Outperform
2022-03-01	Eingeleitet	Wells Fargo	Overweight
2022-02-18	Eingeleitet	SMBC Nikko	Outperform
2021-12-16	Eingeleitet	Guggenheim	Buy
2021-07-16	Eingeleitet	Needham	Buy
2021-06-24	Eingeleitet	Truist	Buy
2021-06-15	Eingeleitet	BTIG Research	Buy
2021-06-09	Eingeleitet	Wedbush	Outperform
2021-06-08	Eingeleitet	JMP Securities	Mkt Outperform
2021-05-19	Eingeleitet	Cantor Fitzgerald	Overweight
2021-05-11	Resumed	Jefferies	Buy
2021-02-24	Eingeleitet	William Blair	Outperform
2021-01-05	Eingeleitet	Oppenheimer	Outperform
2020-10-19	Eingeleitet	Chardan Capital Markets	Buy
2020-10-19	Eingeleitet	Goldman	Buy
2020-10-19	Eingeleitet	Jefferies	Buy
2020-10-19	Eingeleitet	Morgan Stanley	Overweight

Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	9.77	8.33	15.45	2.50	0.00
Research and development USD (M)	86.40	66.00	56.78	91.17	131.94
Operating expenses USD (M)	120.27	99.79	87.89	164.95	173.27
Operating income USD (M)	-110.50	-91.46	-72.44	-162.45	-173.27
Income before tax USD (M)	-	-	-111.57	-166.01	-174.52
Income tax expense USD (M)	0.00	0.00	0.00	0.00	-
Net income USD (M)	-109.00	-89.30	-111.57	-166.01	-174.52
Basic EPS USD/shares	-0.34	-0.36	-0.96	-3.78	-
Diluted EPS USD/shares	-0.34	-0.36	-0.96	-3.78	-
Basic weighted shares shares (M)	319.71	250.13	116.12	43.95	-
Diluted weighted shares shares (M)	319.71	250.13	116.12	43.95	-

Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel

Nagendran SukumarJul 10 '26
Officer
Transaktion
Proposed Sale
Kosten
$6.49
#Aktien
200,000
Wert ($)
1,298,000
#Aktien Gesamt
0
Nagendran SukumarJul 10 '26
President and Head of R&D
Transaktion
Sale
Kosten
$6.24
#Aktien
200,000
Wert ($)
1,248,000
#Aktien Gesamt
936,410
Nagendran SukumarApr 10 '26
Officer
Transaktion
Proposed Sale
Kosten
$4.63
#Aktien
200,000
Wert ($)
926,000
#Aktien Gesamt
0
Nagendran SukumarApr 10 '26
President and Head of R&D
Transaktion
Sale
Kosten
$4.46
#Aktien
200,000
Wert ($)
892,000
#Aktien Gesamt
1,136,410
Nagendran SukumarApr 10 '26
President and Head of R&D
Transaktion
Option Exercise
Kosten
$1.71
#Aktien
19,021
Wert ($)
32,526
#Aktien Gesamt
1,336,410
Rumana Haque-AhmedFeb 27 '26
Officer
Transaktion
Proposed Sale
Kosten
$4.57
#Aktien
2,405
Wert ($)
10,991
#Aktien Gesamt
0
Kamran AlamFeb 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$4.72
#Aktien
1,655
Wert ($)
7,812
#Aktien Gesamt
0
Rumana Haque-AhmedFeb 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$4.72
#Aktien
697
Wert ($)
3,290
#Aktien Gesamt
0
Sean McAuliffeFeb 04 '26
Affiliate - Chief Business Off
Transaktion
Proposed Sale
Kosten
$4.72
#Aktien
914
Wert ($)
4,314
#Aktien Gesamt
0
Fred PorterFeb 04 '26
Affiliate-Chief of Staff &
Transaktion
Proposed Sale
Kosten
$4.72
#Aktien
889
Wert ($)
4,196
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Nagendran Sukumar	Officer	Jul 10 '26	Proposed Sale	$6.49	200,000	1,298,000	0
Nagendran Sukumar	President and Head of R&D	Jul 10 '26	Sale	$6.24	200,000	1,248,000	936,410
Nagendran Sukumar	Officer	Apr 10 '26	Proposed Sale	$4.63	200,000	926,000	0
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Sale	$4.46	200,000	892,000	1,136,410
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Option Exercise	$1.71	19,021	32,526	1,336,410
Rumana Haque-Ahmed	Officer	Feb 27 '26	Proposed Sale	$4.57	2,405	10,991	0
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	$4.72	1,655	7,812	0
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	$4.72	697	3,290	0
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	$4.72	914	4,314	0
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	$4.72	889	4,196	0

Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten

Oct 02, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 02, 2026

Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more. - Stock Titan

Oct 02, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026

Sep 11, 2026

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha

Sep 11, 2026

Sep 07, 2026

These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl

Sep 07, 2026

Sep 04, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 04, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 04, 2026

Aug 27, 2026

Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo

Aug 27, 2026

Aug 23, 2026

Certain Common Stock of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - www.marketscreener.com

Aug 23, 2026

Aug 20, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell? - MarketBeat

Aug 20, 2026

TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st

Aug 20, 2026

Aug 19, 2026

Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest Trading - Analyst Drop Coverage - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com

Aug 18, 2026

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail

Aug 18, 2026

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Aug 18, 2026

Aug 14, 2026

RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan

Aug 14, 2026

BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo

Aug 14, 2026

Aug 13, 2026

Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69 - Bull Flag - Vinanet

Aug 13, 2026

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - stocktitan.net

Aug 13, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why - MarketBeat

Aug 13, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Aug 13, 2026

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance

Aug 13, 2026

Aug 12, 2026

Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo

Aug 12, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? - Investing.com

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com India

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Canada

Aug 12, 2026

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 12, 2026

Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView

Aug 12, 2026

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat

Aug 12, 2026

TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 12, 2026